Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 144

1.

Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).

Nies AT, Schaeffeler E, van der Kuip H, Cascorbi I, Bruhn O, Kneba M, Pott C, Hofmann U, Volk C, Hu S, Baker SD, Sparreboom A, Ruth P, Koepsell H, Schwab M.

Clin Cancer Res. 2014 Feb 15;20(4):985-94. doi: 10.1158/1078-0432.CCR-13-1999. Epub 2013 Dec 18.

2.

Can "specific" OCT1 inhibitors be used to determine OCT1 transporter activity toward imatinib?

Burger H, Mathijssen RH, Sparreboom A, Wiemer EA.

Blood. 2013 Jun 13;121(24):4965-6. doi: 10.1182/blood-2013-03-493841. No abstract available.

3.

Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implications.

Hiwase DK, Saunders V, Hewett D, Frede A, Zrim S, Dang P, Eadie L, To LB, Melo J, Kumar S, Hughes TP, White DL.

Clin Cancer Res. 2008 Jun 15;14(12):3881-8. doi: 10.1158/1078-0432.CCR-07-5095.

4.

Interaction of imatinib with human organic ion carriers.

Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A.

Clin Cancer Res. 2008 May 15;14(10):3141-8. doi: 10.1158/1078-0432.CCR-07-4913.

5.

Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.

Hirayama C, Watanabe H, Nakashima R, Nanbu T, Hamada A, Kuniyasu A, Nakayama H, Kawaguchi T, Saito H.

Pharm Res. 2008 Apr;25(4):827-35. Epub 2007 Oct 13.

PMID:
17934801
6.

The hOCT1 SNPs M420del and M408V alter imatinib uptake and M420del modifies clinical outcome in imatinib-treated chronic myeloid leukemia.

Giannoudis A, Wang L, Jorgensen AL, Xinarianos G, Davies A, Pushpakom S, Liloglou T, Zhang JE, Austin G, Holyoake TL, Foroni L, Kottaridis PD, Müller MC, Pirmohamed M, Clark RE.

Blood. 2013 Jan 24;121(4):628-37. doi: 10.1182/blood-2012-01-405035. Epub 2012 Dec 5.

7.

OCT1 and imatinib transport in CML: is it clinically relevant?

Watkins DB, Hughes TP, White DL.

Leukemia. 2015 Oct;29(10):1960-9. doi: 10.1038/leu.2015.170. Epub 2015 Jul 9. Review.

PMID:
26122430
8.

Reduced ABCG2 and increased SLC22A1 mRNA expression are associated with imatinib response in chronic myeloid leukemia.

de Lima LT, Vivona D, Bueno CT, Hirata RD, Hirata MH, Luchessi AD, de Castro FA, de Lourdes F Chauffaille M, Zanichelli MA, Chiattone CS, Hungria VT, Guerra-Shinohara EM.

Med Oncol. 2014 Mar;31(3):851. doi: 10.1007/s12032-014-0851-5. Epub 2014 Jan 29.

PMID:
24469953
9.

A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.

Grinfeld J, Gerrard G, Alikian M, Alonso-Dominguez J, Ale S, Valgañon M, Nteliopoulos G, White D, Marin D, Hedgley C, O'Brien S, Clark R, Goldman JM, Milojkovic D, Apperley JF, Foroni L.

Br J Haematol. 2013 Dec;163(5):631-9. doi: 10.1111/bjh.12591. Epub 2013 Oct 10.

PMID:
24117365
10.

OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.

Koren-Michowitz M, Buzaglo Z, Ribakovsky E, Schwarz M, Pessach I, Shimoni A, Beider K, Amariglio N, le Coutre P, Nagler A.

Eur J Haematol. 2014 Apr;92(4):283-8. doi: 10.1111/ejh.12235. Epub 2013 Dec 18.

PMID:
24215657
11.

Does the haplotype Met408-Del420, which was apparently predictive for imatinib efficacy, really exist and how strongly may it affect OCT1 activity?

Tzvetkov MV, Seitz T, Bokelmann K, Mueller T, Brockmöller J, Koepsell H.

Blood. 2014 Feb 27;123(9):1427-9. doi: 10.1182/blood-2013-11-535864. No abstract available.

12.

SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.

Singh O, Chan JY, Lin K, Heng CC, Chowbay B.

PLoS One. 2012;7(12):e51771. doi: 10.1371/journal.pone.0051771. Epub 2012 Dec 18.

13.

Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1.

Gromicho M, Dinis J, Magalhães M, Fernandes AR, Tavares P, Laires A, Rueff J, Rodrigues AS.

Leuk Lymphoma. 2011 Oct;52(10):1980-90. doi: 10.3109/10428194.2011.584005. Epub 2011 Jun 12.

PMID:
21663515
14.

Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.

Yamakawa Y, Hamada A, Uchida T, Sato D, Yuki M, Hayashi M, Kawaguchi T, Saito H.

Biol Pharm Bull. 2014;37(8):1330-5.

15.

From in vitro to in vivo: intracellular determination of imatinib and nilotinib may be related with clinical outcome.

Bouchet S, Dulucq S, Pasquet JM, Lagarde V, Molimard M, Mahon FX.

Leukemia. 2013 Aug;27(8):1757-9. doi: 10.1038/leu.2013.13. Epub 2013 Jan 16. No abstract available.

PMID:
23392357
16.

Adiponectin signals through Adiponectin Receptor 1 to reverse imatinib resistance in K562 human chronic myeloid leukemia cells.

Wu S, Zheng C, Chen S, Lin B, Chen Y, Zhou W, Li Z.

Biochem Biophys Res Commun. 2015 Jan 2;456(1):367-72. doi: 10.1016/j.bbrc.2014.11.089. Epub 2014 Dec 2.

PMID:
25475722
17.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
18.

[Study on imatinib trough concentration, efficacy and their relation in chronic myelocytic leukemia].

Zhong JS, Meng FY, Xu D, Zhou HS, Dai M.

Zhonghua Xue Ye Xue Za Zhi. 2012 Mar;33(3):177-82. Chinese.

PMID:
22781602
19.

Association between imatinib-resistant BCR-ABL mutation-negative leukemia and persistent activation of LYN kinase.

Wu J, Meng F, Kong LY, Peng Z, Ying Y, Bornmann WG, Darnay BG, Lamothe B, Sun H, Talpaz M, Donato NJ.

J Natl Cancer Inst. 2008 Jul 2;100(13):926-39. doi: 10.1093/jnci/djn188. Epub 2008 Jun 24.

20.

P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate.

Illmer T, Schaich M, Platzbecker U, Freiberg-Richter J, Oelschlägel U, von Bonin M, Pursche S, Bergemann T, Ehninger G, Schleyer E.

Leukemia. 2004 Mar;18(3):401-8.

PMID:
14724652

Supplemental Content

Support Center